Rallybio Corporation (RLYB) Stock Price & Analysis

Rallybio Corporation (RLYB) closed at USD 16.4 on Thursday, October 22, 2026, up 0.52% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 16.4; the Oct 22, 2026 session ranged USD 16.2–16.4 on volume of 5,521 shares. Market capitalization is —, with a 52-week range of USD 3.67–17.57 (NCM). Source: Nexqual, retrieved October 23, 2026 at 09:26 UTC.

Also available as compact Markdown for AI agents: nexqual.com/RLYB.md

Key facts (RLYB)

Last four reported quarters (through Jun 30, 2026): revenue $646K, net income $45.6M (7051.2% margin) (SEC filings).
1 of 80 tracked superinvestors hold RLYB (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
Total return with dividends: 1Y +241.7% vs S&P 500 +14.9%; 5Y -87.4% vs S&P 500 +80.3%.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (RLYB)

USD	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	—	—	—	$636K	$858K	$646K
Operating income	-$45.6M	-$67.9M	-$78.9M	-$60.5M	-$33.1M	-$27.7M
Net income	-$47.0M	-$66.7M	-$74.6M	-$57.8M	-$9.0M	$45.6M
EPS (diluted)	-$14.72	-$16.72	-$14.72	-$10.61	-$1.59	—
Free cash flow	-$45.9M	-$57.3M	-$60.3M	-$49.3M	—	—
Operating margin	—	—	—	-9511.9%	-3853.6%	-4291.5%
Net margin	—	—	—	-9084.1%	-1046.4%	7051.2%
Revenue growth	—	—	—	—	+34.9%	—
Cash + short-term investments	$175M	$169M	$110M	$65.5M	$54.7M	—

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (RLYB)

Superinvestors (SEC 13F-HR, Q2 2026) (RLYB)

1 of 80 tracked investors hold RLYB. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Investor	Firm	% of portfolio	Value	Change
Viking Global	Viking Global Investors	0.02%	$8.4M	Unchanged

Total return (dividends reinvested) (RLYB)

	1Y (from 2025-10-23)	5Y (from 2021-10-18)
Total return	+241.7%	-87.4%
S&P 500 (SPY)	+14.9%	+80.3%
Per year	+243.1%	-33.8%
Volatility (annualized)	76.5%	96.7%
Max drawdown	-31.1% (Dec 2025→Feb 2026)	-98.7% (Nov 2021→Apr 2025)

Companies that name RLYB in their SEC reports

Relationship to RLYB	Company	Filing	Sentence
partner	RECURSION PHARMACEUTICALS, INC. (RXRX)	10-K Feb 25, 2026	“In addition to capital raising issuances, in connection with the acquisitions of Cyclica Inc. (Cyclica) and Valence Discovery Inc. (Valence) in May 2023, we issued 12.4 million shares of our Class A common stock or securities convertible or exchangeable into Class A common stock; in November 2024, we issued approximately 102.1 million shares of our Class A common stock in connection with our business combination w…”

RLYB analyst estimates and revisions

Period	EPS estimate	90 days ago	Change	Revenue estimate	Analysts
Current quarter (ends Sep 2026)	$-1.44	$-1.44	+0.0%	$0	1
Next quarter (ends Dec 2026)	$-1.60	$-1.60	+0.0%	$0	1
Current fiscal year (ends Dec 2026)	$-5.52	$-9.17	-39.8%	$0	1
Next fiscal year (ends Dec 2027)	$-3.60	$-3.60	+0.0%	$0	1

Key Statistics (as of October 23, 2026 at 09:26 UTC)

Price	USD 16.4
Change	▲ 0.52% (up)
Previous Close	USD 16.4
Open	USD 16.4
Day Range	USD 16.2 – 16.4
52-Week Range	USD 3.67 – 17.57
Volume	5,521 shares
Market Cap	—
Exchange	NCM

Technical Analysis (RLYB)

Nexqual's technical model rates RLYB "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 09:26 UTC.

Overall Signal	STRONG SELL
RSI (14)	42.89 (neutral)
vs SMA50	Below (USD 16.84)
MACD	-0.13 (negative)

Earnings (RLYB)

EPS Estimate	USD -1.44
Revenue Estimate	$0

Recent Earnings History

Quarter	Actual vs Estimate
2026-06-30	USD -0.85 vs est -1.28 ▲ beat
2026-03-31	USD -1.46 vs est -1.2 ▼ miss
2025-12-31	USD -1.52 vs est -1.24 ▼ miss
2025-09-30	USD 2.88 vs est -1.56 ▲ beat

Source: Nexqual, October 23, 2026 at 09:26 UTC.

Financials & Fundamentals (RLYB)

Total Revenue	$646,000
Gross Margin	+0.00%
Operating Margin	-3935.45%
Profit Margin	+7051.24%
ROE	+64.86%
Current Ratio	27.27
Total Cash	$92.85M
Total Debt	$0

Source: Nexqual, October 23, 2026 at 09:26 UTC.

Financial Health Score (RLYB)

Nexqual rates Rallybio Corporation's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 09:26 UTC.

Growth	Strong — Revenue +35% YoY (annual)
Profitability	Critical — Heavily loss-making — early-stage company
Balance Sheet	Mixed — $93M cash, no debt
Cash Flow	Weak — Operating cash flow -$30M (FY ended Dec 2025, 10-K)
Efficiency	Strong — ROE 65%, ROA -21.3%

Ownership (RLYB)

Insider Ownership	+24.99%
Institutional Ownership	+84.33%
Shares Outstanding	5.31M
Float	1.70M
Short % of Float	+1.11%

Source: Nexqual, October 23, 2026 at 09:26 UTC.

Peers & Related Stocks

Symbol	Name	Price	Change
LGND	Ligand Pharmaceuticals Incorpor	USD 307.82	▼ 2.21%
RYTM	Rhythm Pharmaceuticals, Inc.	USD 90.9	▲ 2.57%
IOVA	Iovance Biotherapeutics, Inc.	USD 14.14	▼ 3.28%
PRAX	Praxis Precision Medicines, Inc	USD 258.92	▲ 0.96%
IONS	Ionis Pharmaceuticals, Inc.	USD 43.91	▼ 0.81%
ABVX	Abivax SA	USD 90.23	▼ 3.49%

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:26 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt